Theravance Biopharma (TBPH) Other Non-Current Liabilities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Other Non-Current Liabilities data on file, last reported at $244000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 81.04% year-over-year to $244000.0 in Q1 2026; TTM through Mar 2026 was $244000.0, a 81.04% decrease from a year earlier, with the FY2025 full-year figure at $313000.0, down 99.63% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $244000.0, down from $313000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for TBPH reached as high as $83.7 million in Q4 2024 and fell as low as $244000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $20.5 million across 5 years, with a median of $5.0 million in 2024.
• Across the five-year window, Other Non-Current Liabilities jumped 2301.72% in 2022 and sank 99.63% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $76.0 million in 2022, then climbed by 4.57% to $79.5 million in 2023, then increased by 5.32% to $83.7 million in 2024, then sank by 99.63% to $313000.0 in 2025, then dropped by 22.04% to $244000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $244000.0 in Q1 2026, $313000.0 in Q4 2025, and $313000.0 in Q3 2025.